In the Pipeline

Our pipeline is focused on therapeutic areas where we believe we have the best opportunity to deliver transformational medicines to patients.

Our Pipeline at a Glance as of October 13, 2017

35

Compounds in Development

 

We are transforming the way serious diseases are treated. Our pipeline currently has 35 compounds in development, focused on key therapeutic areas.


Immuno-Oncology Interactive Pipeline

See why effector cells are at the center of our research universe.


Disease Area 

Click on the therapeutic areas to learn more.

In the Pipeline

No filter applied. Showing 0 of 0 compounds.
Sort By

Generic Name /

Compound

Brand Name
Phase
Modality / Compound
Disease Area
* Virology assets removed with sale of virology R&D pipeline to ViiV Healthcare on Feb 22. Bristol-Myers Squibb continues development for HCV assets including Daklinza, Sunvepra and beclabuvir (NS5B Non Nuc) in select markets.
Please click on product name to see the Full U.S. Prescribing Information for ELIQUIS®, EMPLICITI™, NULOJIX®, OPDIVO®, ORENCIA®, SPRYCEL®, YERVOY®, including Boxed WARNINGS for ELIQUIS®, NULOJIX®, and Boxed WARNING for YERVOY® regarding immune-mediated adverse reactions.


 

Phase I – clinical trials investigating safety of an investigational medicine in a small number of human subjects.

Phase II – clinical trials investigating dosing, safety and efficacy of an investigational medicine in a small number of patients who have the disease or condition under study.

Phase III – clinical trials investigating the safety and efficacy of an investigational medicine in a larger number of patients who have the disease or condition under study. For purposes of this chart, this includes the regulatory approval process prior to receiving marketing approval in the first major market.

Marketed Product Development – clinical trials investigating new uses or formulations regarding medicines that have already received regulatory approval for at least one indication in a major market.


Like any other scientific endeavor, clinical testing of novel drug compounds is a complex, time-consuming, resource-intensive process with no guaranteed results. But, as described here, Bristol-Myers Squibb is committed to pursuing such clinical development and, in doing so, to bringing new hope to patients.